Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pivotal Phase II Clinical Trial evaluating PolyPEPI1018 in combination with toripalimab in refractory MSS Colorectal Cancer

Next Previous
Trial Profile

A Pivotal Phase II Clinical Trial evaluating PolyPEPI1018 in combination with toripalimab in refractory MSS Colorectal Cancer

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 31 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PolyPEPI 1018 (Primary) ; Toripalimab (Primary) ; Bevacizumab; Tipiracil/trifluridine
  • Indications Colorectal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms OBERTO-202

Most Recent Events

  • 31 Oct 2025 New trial record
  • 27 Aug 2025 According to a TREOS Bio Ltd. media release, the company secured dollar 2.1 million in bridge financing to support the initiation of pivotal Phase II study in 140 patients with microsatellite stable (MSS) metastatic colorectal cancer (CRC).
  • 27 Aug 2025 According to a TREOS Bio Ltd. media release, Prof. Sebastian Stintzing is the principal investigator Charite-Universitatsmedizin Berlin.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top